Skip to main content Accessibility help
×
Home

Prevention of Clostridium difficile Infection: A Systematic Survey of Clinical Practice Guidelines

  • Lyubov Lytvyn (a1) (a2), Dominik Mertz (a1) (a3) (a4), Behnam Sadeghirad (a1) (a5), Faisal Alaklobi (a6), Anna Selva (a7) (a8), Pablo Alonso-Coello (a7) (a8) and Bradley C. Johnston (a1) (a2) (a9) (a10)...

Abstract

BACKGROUND

Clostridium difficile infection (CDI) is the most common cause of hospital-acquired infectious diarrhea.

OBJECTIVE

To analyze the methodological quality, content, and supporting evidence among clinical practice guidelines (CPGs) on CDI prevention.

DESIGN AND SETTING

We searched medical databases and gray literature for CPGs on CDI prevention published January 2004-January 2015. Three reviewers independently screened articles and rated CPG quality using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument, composed of 23 items, rated 1–7, within 6 domains. We reported each domain score as a percentage of its maximum possible score and standardized range. We summarized recommendations, extracted their supporting articles, and rated individually the level of evidence using the Oxford Centre for Evidence-Based Medicine Levels of Evidence.

RESULTS

Of 2,578 articles screened, 5 guidelines met inclusion criteria. Median AGREE II scores and interquartile ranges were: clarity of presentation, 75.9% (75.9%–79.6%); scope and purpose, 74.1% (68.5%–85.2%); editorial independence, 63.9% (47.2%–66.7%); applicability, 43.1% (19.4%–55.6%); stakeholder involvement, 40.7% (38.9%–44.4%); and rigor of development, 18.1% (17.4%–35.4%). CPGs addressed several common strategies for CDI prevention, including antibiotic stewardship, hypochlorite solutions, probiotic prophylaxis, and bundle strategies. Recommendations were often not consistent with evidence, and most were based on low-level studies.

CONCLUSION

CPGs did not adhere well to AGREE II reporting standards. Furthermore, there was limited transparency in moving from evidence to recommendations. CDI prevention CPGs need to better adhere to AGREE-II and be transparent in moving from evidence to recommendations, and recommendations need to be consistent with available evidence.

Infect Control Hosp Epidemiol 2016;37:901–908

Copyright

Corresponding author

Address correspondence to Bradley C. Johnston, PhD, The Hospital for Sick Children Research Institute, Peter Gilgan Centre for Research and Learning, 686 Bay St, Rm 11.9859 West, Toronto, ON, Canada, M5G 0A4 (bradley.johnston@sickkids.ca).

References

Hide All
1. Dubberke, ER, Butler, AM, Reske, KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008;14:10311038.
2. Chitnis, AS, Holzbauer, SM, Belflower, RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013;173:13591367.
3. Hebert, C, Du, H, Peterson, LR, Robicsek, A. Electronic health record-based detection of risk factors for Clostridium difficile infection relapse. Infect Control Hosp Epidemiol 2013;34:407414.
4. Ricciardi, R, Rothenberger, DA, Madoff, RD, Baxter, NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624631.
5. Freeman, J, Bauer, MP, Baines, SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529549.
6. Louie, TJ, Miller, MA, Crook, DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013;61:222230.
7. Stevens, V, Dumyati, G, Fine, LS, Fisher, SG, van Wijngaarden, E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53:4248.
8. Hensgens, MP, Goorhuis, A, Dekkers, OM, Kuijper, EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012;67:742748.
9. Slimings, C, Riley, TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881891.
10. Ghantoji, SS, Sail, K, Lairson, DR, DuPont, HL, Garey, KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010;74:309318.
11. Nanwa, N, Kendzerska, T, Krahn, M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol 2015;110:511519.
12. Sydnor, ERM, Perl, TM. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev 2011;24:141173.
13. Field, MJ, Lohr, KN. Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academy Press; 1990.
14. Hayward, RA, Wilson, MC, Tunis, SR, Bass, EB, Guyatt, G. Users’ guides to the medical literature, VIII: how to use clinical practice guidelines, A: are the recommendations valid? JAMA 1995;274:570574.
15. Shaneyfelt, TM, Centor, RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA 2009;301:868869.
16. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:1823.
17. Brouwers, MC, Kho, ME, Browman, GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839E842.
18. Carrico, RM, Bryant, K, Lessa, F, Limbago, B, Litz Fauerbach, L, Marx, JF. Guide to preventing Clostridium difficile infections. APIC website. http://apic.org/Resource_/EliminationGuideForm/e3a85b7e-7ad8-4ab6-9892-54aef516cf10/File/2013CDiffFinal.pdf. Published 2013. Accessed February 14, 2015.
19. Hawkey, P, Bain, L, Borriello, P, et al. Clostridium difficile infection: how to deal with the problem. Public Health England and Department of Health 2008.
20. OCEBM Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine website. http://www.cebm.net/index.aspx?o=5653. Published 2011. Accessed February 14, 2015.
21. Howick, J, Chalmers, I, Glasziou, P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). Oxford Centre for Evidence-Based Medicine website. http://www.cebm.net/index.aspx?o=5653. Published 2011. Accessed April 21, 2016.
22. Cohen, J. Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213.
23. Acuña-Izcaray, A, Sánchez-Angarita, E, Plaza, V, et al. Quality assessment of asthma clinical practice guidelines: a systematic appraisal. Chest 2013;144:390397.
24. Koch, GG. Intraclass correlation coefficient. Ency Stat Sci 1982.
25. Kramer, MS, Feinstein, AR. Clinical biostatistics, LIV: the biostatistics of concordance. Clin Pharmacol Ther 1981;29:111123.
26. Surawicz, CM, Brandt, LJ, Binion, DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478498.
27. Vonberg, RP, Kuijper, E, Wilcox, M, et al. Infection control measures to limit the spread of Clostridium difficile . Clin Microbiol Infect 2008;14:220.
28. Dubberke, ER, Carling, P, Carrico, R, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control 2014;35:628645.
29. Debast, S, Bauer, M, Kuijper, E. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20:126.
30. Steinberg, E, Greenfield, S, Mancher, M, Wolman, DM, Graham, R. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press, 2011.
31. Goldenberg, JZ, Ma, SS, Saxton, JD, et al. Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095.
32. Guyatt, G, Akl, EA, Hirsh, J, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med 2010;152:738741.
33. Eliopoulos, GM, Harris, AD, Bradham, DD, et al. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis 2004;38:15861591.
34. Stone, SP, Cooper, BS, Kibbler, CC, et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. Lancet Infect Dis 2007;7:282288.
35. Turner, T, Misso, M, Harris, C, Green, S. Development of evidence-based clinical practice guidelines (CPGs): comparing approaches. Implement Sci 2008;3:45.
36. Kung, J, Miller, RR, Mackowiak, PA. Failure of clinical practice guidelines to meet Institute of Medicine standards: two more decades of little, if any, progress. Arch Intern Med 2012;172:16281633.
37. Alonso-Coello, P, Irfan, A, Solà, I, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care 2010;19:e58.
38. Gagliardi, AR, Brouwers, MC. Do guidelines offer implementation advice to target users? A systematic review of guideline applicability. BMJ Open 2015;5:e007047.
39. Al-Ansary, LA, Tricco, AC, Adi, Y, et al. A systematic review of recent clinical practice guidelines on the diagnosis, assessment and management of hypertension. PLOS ONE 2013;8:e53744.
40. Hsu, J, Abad, C, Dinh, M, Safdar, N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol 2010;105:23272339.
41. Khanafer, N, Voirin, N, Barbut, F, Kuijper, E, Vanhems, P. Hospital management of Clostridium difficile infection: a review of the literature. J Hosp Infect 2015;90:91101.
42. Brozek, J, Akl, E, Falck-Ytter, Y, et al. 046 Guideline development tool (GDT)—web-based solution for guideline developers and authors of systematic reviews. BMJ Qual Saf 2013;22:A26.
43. Shekelle, P, Woolf, S, Grimshaw, J, Schunemann, H, Eccles, M. Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. Implement Sci 2012;7:62.
44. Browman, GP, Somerfield, MR, Lyman, GH, Brouwers, MC. When is good, good enough? Methodological pragmatism for sustainable guideline development. Implement Sci 2015;10:222.
45. Andrews, J, Guyatt, G, Oxman, AD, et al. GRADE guidelines, 14: going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719725.
46. Tricoci, P, Allen, JM, Kramer, JM, Califf, RM, Smith, SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301:831841.
Type Description Title
WORD
Supplementary materials

Lytvyn supplementary material
Tables S1-S8

 Word (52 KB)
52 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed